Cellular uptake and internalization of hyaluronan-based doxorubicin and cisplatin conjugates

Journal of Drug Targeting

Volumn 22, Issue 7, 2014, Pages 648-657

  Cai, Shuang ^a,b   Alhowyan, Adel Ali B ^a   Yang, Qiuhong ^a   Forrest, W C Melanie ^b   Shnayder, Yelizaveta ^c   Forrest, M Laird ^a,b  

^a UNIVERSITY OF KANSAS   (United States)

^b HylaPharm   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

CD44 receptors; Cisplatin; Doxorubicin; Hyaluronan; Internalization mechanism

Indexed keywords

CISPLATIN; DOXORUBICIN; HERMES ANTIGEN; HYALURONIC ACID; ANTINEOPLASTIC AGENT; DRUG CARRIER; LIGAND; NANOCONJUGATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONJUGATION; CONTROLLED STUDY; DRUG UPTAKE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; XENOGRAFT; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CULTURE TECHNIQUE; DRUG SCREENING; FEMALE; FLUORESCENCE MICROSCOPY; METABOLISM; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CISPLATIN; DOXORUBICIN; DRUG CARRIERS; FEMALE; HUMANS; HYALURONIC ACID; LIGANDS; MICE, SCID; MICROSCOPY, FLUORESCENCE; MOLECULAR STRUCTURE; NANOCONJUGATES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904336797     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2014.921924     Document Type: Article

References (29)

1. Fraser JR, Laurent TC, Laurent UB. Hyaluronan: Its nature, distribution, functions and turnover. J Intern Med 1997;242:27-33
2. Cai S, Thati S, Bagby TR, et al. Localized doxorubicin chemotherapy with a biopolymeric nanocarrier improves survival and reduces toxicity in xenografts of human breast cancer. J Control Release 2010;146:212-18
3. Cai S, Xie Y, Bagby TR, Cohen MS, Forrest ML. Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate. J Surg Res 2008;147:247-52
4. Cai S, Xie Y, Davies NM, et al. Carrier-based intralymphatic cisplatin chemotherapy for the treatment of metastatic squamous cell carcinoma of the head, neck. Ther Deliv 2010;1:237-45
5. Cai S, Xie Y, Davies NM, et al. Pharmacokinetics and disposition of a localized lymphatic polymeric hyaluronan conjugate of cisplatin in rodents. J Pharm Sci 2010;99:2664-71
6. Cohen MS, Cai S, Xie Y, Forrest ML. A novel intralymphatic nanocarrier delivery system for cisplatin therapy in breast cancer with improved tumor efficacy and lower systemic toxicity in vivo. Am J Surg 2009;198:781-6
7. Xie Y, Aillon KL, Cai S, et al. Pulmonary delivery of cisplatinhyaluronan conjugates via endotracheal instillation for the treatment of lung cancer. Int J Pharm 2010;392:156-63
8. Yue C, Liu P, Zheng M, et al. IR-780 dye loaded tumor targeting theranostic nanoparticles for NIR imaging and photothermal therapy. Biomaterials 2013;34:6853-61
9. Zhao H, Duong HH, Yung LY. Folate-conjugated polymer micelles with Ph-Triggered drug release properties. Macromol Rapid Commun 2010;31:1163-9
10. Singh M, Atwal H, Micetich R. Transferrin directed delivery of adriamycin to human cells. Anticancer Res 1998;18:1423-7
11. Lunov O, Syrovets T, Rocker C, et al. Lysosomal degradation of the carboxydextran shell of coated superparamagnetic iron oxide nanoparticles and the fate of professional phagocytes. Biomaterials 2010;31:9015-22
12. Malugin A, Kopeckova P, Kopecek J. Liberation of doxorubicin from HPMA copolymer conjugate is essential for the induction of cell cycle arrest and nuclear fragmentation in ovarian carcinoma cells. J Control Release 2007;124:6-10
13. Sakai-Kato K, Ishikura K, Oshima Y, et al. Evaluation of intracellular trafficking and clearance from HeLa cells of doxorubicin-bound block copolymers. Int J Pharm 2012;423: 401-9
14. Duvvuri M, Gong Y, Chatterji D, Krise JP. Weak base permeability characteristics influence the intracellular sequestration site in the multidrug-resistant human leukemic cell line HL-60. J Biol Chem 2004;279:32367-72
15. Majumdar S, Tejo BA, Badawi AH, et al. Effect of modification of the physicochemical properties of ICAM-1-derived peptides on internalization and intracellular distribution in the human leukemic cell line HL-60. Mol Pharm 2009;6:396-406
16. Hall CL, Collis LA, Bo AJ, et al. Fibroblasts require protein kinase C activation to respond to hyaluronan with increased locomotion. Matrix Biol 2001;20:183-92
17. Johnson LA, Prevo R, Clasper S, Jackson DG. Inflammationinduced uptake and degradation of the lymphatic endothelial hyaluronan receptor LYVE-1. J Biol Chem 2007;282:33671-80
18. Shigeishi H, Fujimoto S, Hiraoka M, et al. Overexpression of the receptor for hyaluronan-mediated motility, correlates with expression of microtubule-Associated protein in human oral squamous cell carcinomas. Int J Oncol 2009;34:1565-71
19. Yamano Y, Uzawa K, Shinozuka K, et al. Hyaluronan-mediated motility: A target in oral squamous cell carcinoma. Int J Oncol 2008;32:1001-9
20. Mouta Carreira C, Nasser SM, Di Tomaso E, et al. LYVE-1 is not restricted to the lymph vessels: Expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. Cancer Res 2001;61:8079-84
21. Chang C, Wang P, Yang H, et al. Expression of LYVE-1 and Prox-1 in non-small cell lung cancer and the relationship with lymph node metastasis. Sichuan Da Xue Xue Bao Yi Xue Ban 2011;42:174-8
22. Bairey O, Bishara J, Stahl B, Shaklai M. Severe tissue necrosis after cisplatin extravasation at low concentration: Possible "immediate recall phenomenon". J Natl Cancer Inst 1997;89:1233-4
23. Dernell WS, Withrow SJ, Straw RC, Lafferty MH. Adjuvant chemotherapy using cisplatin by subcutaneous administration. In Vivo 1997;11:345-50
24. Venable R, Worley D, Gustafson D, et al. Hyaluronan cisplatin conjugate in five dogs with soft tissue sarcomas. Am J Vet Res 2012;73:1969-76
25. Joshua B, Kaplan MJ, Doweck I, et al. Frequency of cells expressing CD44, a head and neck cancer stem cell marker: Correlation with tumor aggressiveness. Head Neck 2012;34:42-9
26. Rademaker-Lakhai JM, Terret C, Howell SB, et al. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin Cancer Res 2004;10:3386-95
27. Chang G, Li C, Lu W, Ding J. N-Boc-histidine-capped PLGAPEG-PLGA as a smart polymer for drug delivery sensitive to tumor extracellular pH. Macromol Biosci 2010;10:1248-56
28. Yuba E, Tajima N, Yoshizaki Y, et al. Dextran derivative-based Ph-sensitive liposomes for cancer immunotherapy. Biomaterials 2014;35:3091-101
29. Yae T, Tsuchihashi K, Ishimoto T, et al. Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat Commun 2012;3:883 (1-10.